Pantop D

# Pantop D ## Overview - **Classification**: Proton Pump Inhibitor (Pantoprazole) + Dopamine Antagonist/Prokinetic (Domperidone). - **Mechanism**: Pantoprazole irreversibly inhibits gastric H+/K+ ATPase, reducing acid secretion. Domperidone is a D2 antagonist, increasing GI motility and acting as an antiemetic. ## Primary Indications 1. **Gastroesophageal Reflux Disease (GERD)**: Especially with associated nausea, vomiting, or delayed gastric emptying. 2. **Dyspepsia**: Functional dyspepsia or acid-related dyspepsia with symptoms like bloating, epigastric pain, nausea. 3. **Erosive Esophagitis**: When co-existing with symptoms requiring prokinetic action. ## Adult Dosing ### Standard Dosing **GERD / Dyspepsia / Erosive Esophagitis** - **Dose**: **Pantoprazole 40 mg / Domperidone 10 mg** - **Frequency**: **Once daily** - **Route**: Oral - **Duration**: Up to **4-8 weeks** for GERD/esophagitis; re-evaluate need. - **Special consideration**: Take **15-30 minutes before breakfast**. ### Dose Adjustments - **Renal Impairment**: - **CrCl < 30 mL/min (severe)**: Consider reducing Domperidone frequency to once daily. - Monitor for Domperidone adverse effects. - **Hepatic Impairment**: - **Contraindicated** in moderate to severe hepatic impairment (due to Domperidone). - Pantoprazole alone may be used with caution (max **20 mg/day** in severe). - **Elderly Patients**: Use lowest effective dose for shortest duration. - Increased risk of cardiac events (Domperidone) and PPI-related adverse effects. ## Pediatric Dosing ### Neonates (0-28 days) - **Not recommended**: Pantop D FDC is generally not recommended. - **Special Notes**: Domperidone carries significant cardiac risks (QT prolongation, arrhythmias) in this age group. ### Infants (1-12 months) - **Not recommended**: Pantop D FDC is generally not recommended. - **Special Notes**: Similar safety concerns for Domperidone as in neonates. Lack of established dosing. ### Children (1-12 years) - **Not recommended**: Pantop D FDC is generally not recommended. - **Special Notes**: Single-agent therapy (e.g., Pantoprazole alone) may be considered if indicated. ### Adolescents (13-18 years) - **Dose**: Use with extreme caution, only if benefits outweigh risks. - If considered: **Pantoprazole 20-40 mg / Domperidone 10 mg** once daily. - **Maximum**: Adult dose. - **Special Notes**: Weigh risks (Domperidone cardiac effects, extrapyramidal symptoms) vs. benefits. ECG monitoring may be considered. ## Safety Information ### Contraindications - **Absolute**: - Hypersensitivity to pantoprazole, domperidone, or excipients. - **Moderate to severe hepatic impairment**. - **Known prolonged QT interval**, significant cardiac disease (e.g., CHF). - **Concomitant strong CYP3A4 inhibitors** (e.g., ketoconazole, erythromycin) or QT-prolonging drugs. - **Electrolyte disturbances** (hypokalemia, hypomagnesemia). - **Prolactinoma**. - **GI hemorrhage, mechanical obstruction, or perforation**. - **Relative**: Osteoporosis, _C. difficile_ infection risk (long-term PPI). ### Common Adverse Effects - **Very Common (>10%)**: Headache, Nausea, Abdominal pain, Diarrhea (Pantoprazole). - **Common (1-10%)**: Headache, Dry mouth (Domperidone); Dizziness, Flatulence, Rash (Pantoprazole). - **Serious but Rare**: - **Cardiac arrhythmias** (QT prolongation, Torsade de Pointes) (Domperidone). - **Extrapyramidal symptoms** (Domperidone, esp. in children or high doses). - **_Clostridium difficile_-associated diarrhea (CDAD)** (PPI). - **Acute interstitial nephritis, bone fractures, hypomagnesemia** (long-term PPI). ### Key Drug Interactions - **Strong CYP3A4 inhibitors (e.g., ketoconazole, erythromycin, clarithromycin)**: Increase domperidone levels, increasing QT prolongation risk. **Contraindicated**. - **QT-prolonging drugs (e.g., amiodarone, haloperidol)**: Additive QT prolongation risk with domperidone. **Contraindicated**. - **HIV antivirals (e.g., atazanavir, nelfinavir)**: PPIs reduce absorption; avoid concomitant use. - **Methotrexate**: PPIs may increase methotrexate levels; monitor or briefly interrupt PPI. - **Warfarin**: PPIs may increase INR; monitor INR closely. - **Clopidogrel**: PPIs may reduce antiplatelet effect; use with caution. ## Monitoring & Follow-up - **Before Treatment**: Assess cardiac risk factors (Domperidone). Review medications for interactions. - **During Treatment**: - **ECG**: Consider for high-risk patients on Domperidone. - **Electrolytes**: Monitor for hypokalemia, hypomagnesemia with long-term PPI use or Domperidone. - **Clinical Signs**: Monitor for cardiac symptoms (palpitations), extrapyramidal symptoms, signs of CDAD. - **Clinical Signs**: Monitor for persistence of GERD/dyspepsia symptoms. ## Clinical Pearls - 💡 **Timing is Key**: Take Pantop D **15-30 minutes before breakfast** (or first meal) for optimal effect. - 💡 **Domperidone Safety**: Use for the **shortest duration** and at the **lowest effective dose** due to cardiac risks. - 💡 **Pediatric Use**: **Generally not recommended** for children due to Domperidone's safety profile and lack of clear FDC dosing. - 💡 **Hepatic Impairment**: **Contraindicated** in moderate to severe hepatic impairment due to Domperidone. - 💡 **Drug Interactions**: Always review all concomitant medications, especially for CYP3A4 inhibitors or QT-prolonging agents. > **⚠️ Important**: This information is for educational purposes only. Always consult current prescribing information, local guidelines, and clinical judgment before prescribing.